Tumor Lysis Syndrome: Risk-Based Prevention and Treatment

Tumor Lysis Syndrome: Risk-Based Prevention and Treatment: overview

This algorithm matches tumor lysis syndrome prevention to risk and then outlines management of established TLS. Risk depends on tumor type and burden (white count, LDH, bulky disease), baseline renal function, and the therapy, including venetoclax ramp-up in CLL.

Low-risk patients, which includes most solid tumors, need oral hydration with or without allopurinol and laboratory monitoring. Intermediate-risk patients get intravenous hydration and allopurinol started two to three days before treatment, with labs every 8 to 12 hours and rasburicase if uric acid rises. High-risk patients, such as Burkitt lymphoma, bulky aggressive lymphoma, or acute leukemia with high white counts, get aggressive intravenous fluids and rasburicase with labs every 6 to 8 hours; venetoclax in CLL uses a weekly ramp-up with prophylaxis and monitoring set by lymph node size and lymphocyte count. In established TLS, hyperuricemia is treated with rasburicase 0.2 mg/kg after checking G6PD, hyperkalemia with calcium, insulin and glucose and potassium binders under ECG monitoring, and hypocalcemia only if symptomatic because calcium given with high phosphate can deposit in tissues. Early nephrology involvement and dialysis are needed for refractory hyperkalemia, volume overload or uremia. Urine alkalinization is not recommended. No specific trials are linked to this chart.

Background reading: Supportive care board review notes.

Tumor Lysis Syndrome: Risk-Based Prevention and Treatment: the algorithm in words

Prophylaxis by TLS risk, then management of established TLS. Starting point: Starting therapy for a high-burden or chemosensitive cancer. Full background: Supportive care notes.

Low risk (first-line): Most solid tumors: Oral hydration ± allopurinol (monitor labs).
Intermediate risk (first-line): Prevent: IV hydration + allopurinol (labs every 8-12 h; rasburicase if urate rises).
High risk (first-line): Burkitt, bulky, high WBC: Aggressive IV fluids + rasburicase (labs every 6-8 h; consider ICU); Venetoclax (CLL): Ramp-up with risk-based prophylaxis (by node size and lymphocyte count).
Established TLS (first-line): Hyperuricemia: Rasburicase 0.2 mg/kg (check G6PD first); Hyperkalemia: Calcium, insulin + glucose, binders (continuous ECG monitoring); Hypocalcemia: Treat only if symptomatic (high phosphate: Ca-phosphate deposition); Renal failure: Early nephrology, dialysis (refractory K, volume overload, uremia).

Simplified board-prep scaffold; verify against current guidelines. Risk depends on tumor type, burden (WBC, LDH, bulk), renal function and the drug (venetoclax ramp-up). Start allopurinol 2 to 3 days before therapy; urine alkalinization is not recommended. Check G6PD before rasburicase (hemolysis, methemoglobinemia). Draw uric acid on ice after rasburicase.